SERB (Société d’Étude et de Recherche Biologique) is a specialty pharmaceuticals group created in the 50’s.

Our mission has always been to bring lifesaving drugs that meet high unmet medical needs.

The Emergency care franchise has been developed with selected antidotes portfolio answering essential medical needs.

In the last decade, the group has extended its portfolio with acquisitions addressing niche indications, enlarging the Rare Diseases franchise. In addition, SERB has continuously expanded its international presence to ensure a global availability of their medicines.

SERB has accelerated its strategic transformation with a strong acquisition/licensing track record initiated the past 10 years.

Following strategic acquisitions and targeted developments, SERB has succeeded in establishing a consistent drugs portfolio focused on niche specialty pharmaceuticals to ensure continuous availability of life-saving medicines and answer unmet medical needs.

Our commitment is to continue to offer essential drugs meeting Public Health needs.